| Name | Title | Contact Details |
|---|
As of December 31st, 2023, the XFL has officially merged with the USFL to create the United Football League (UFL). Our spring football legacy continues in 2024 under a new name, with the same goal: to make the spring football opportunity as strong as it can be. See you at a game! theUFL.com/tickets
RevGen GENIUS stands as a premier source for aiding businesses in crafting a robust and efficient go-to-market (GTM) strategy. With our expert guidance, clients can drive revenue growth with confidence.
Zawyer Sports & Entertainment brings sports & your brand to life. Follow our family brands, Jacksonville Icemen, Community First Igloo, Savannah Ghost Pirates, Ghost Pirates Ice, Atlanta Gladiators, Allen Americans, Tahoe Knight Monsters, Gastonia Baseball Club, and 32 Degrees Marketing.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.